Overview
The study is trying to answer the following question: "Can we use non-invasive imaging to evaluate the response of atopic dermatitis (eczema) to Dupixent (dupilumab)?"
Description
Participating in this research will allow the subject to undergo a noninvasive imaging alternative to conventional monitoring in response to a biologic. Normally, subjects would undergo a clinical examination, serial photography, and possible biopsies to assess the progression of the disease. This study will get rid of the need for a biopsy but will require multiple scans with non-invasive imaging. This research examines a new approach to monitoring response to a biologic drug used for atopic dermatitis, and can also, be used to grade disease severity without the need for a biopsy.
Eligibility
Inclusion Criteria:
- ≥18 years of age
- Atopic dermatitis (AD) affecting ≥10% body surface area (BSA) at baseline
- IGA score ≥3, on the IGA scale of 0-4 at baseline
- Eczema Area and Severity Index (EASI) score of ≥16 at baseline
Exclusion Criteria:
- Prior treatment with Dupilumab (REGN668/SAR231893)
- Treatment with TCS or topical calcineurin inhibitors (TCI) within 2 weeks before the baseline visit
- Bodyweight <30 kg (65lb) at Baseline
- Known or suspected immunodeficiency including human immunodeficiency virus (HIV) infection
- Pregnancy, breastfeeding or planning to become pregnant or breastfeed during the study